Commonwealth Diagnostics International (CDI) Expands Access to Naturopathic & Integrative Medicine Community Through New Partnership with Rupa Health

SALEM, Mass. - Aug. 23, 2022 - PRLog -- Commonwealth Diagnostics International, Inc. (CDI), an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose common sources of digestive distress and functional gastrointestinal ailments, today announced expanded access to the naturopathic and integrative medicine community through a strategic partnership with Rupa Health, a digital health platform making it easier to practice root cause medicine through a modernized process of ordering specialty labs.

"We are thrilled to partner with Rupa Health and look forward to working together to deliver diagnostic care to patients when and where they need it," said Craig S. Strasnick, President and CEO of CDI. "Making CDI's cost-effective diagnostic solutions available on the Rupa platform will provide greater access to naturopathic and integrative practitioners and their patients nationwide and help expedite treatments with more precise and timely results from our experienced lab staff."

Per the strategic partnership, Rupa will provide services including marketing support and order processing services for CDI's portfolio of industry-leading diagnostic solutions. Tests now available for ordering on the Rupa platform include non-invasive at-home hydrogen and methane breath tests for Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO) as well as fructose, lactose, and sucrose malabsorption.

Continued Strasnick, "The holistic approach to health, wellness, and nutrition strongly emphasizes disease prevention. A central tenant of this approach is that good health starts with good digestion and gut health. Our tests are easy-to-use, quick, and safe for patients and support meaningful GI health outcomes by helping steer a practitioner's approach to dietary modification, homeopathic remedies, nutritional supplementation, immune support, high-quality probiotics, and additional testing."

Founded in 2015 in Salem, Massachusetts, and operating out of its CLIA-certified laboratory and as an FDA-registered, ISO 13485-certified medical device manufacturer, CDI has partnerships with leading health systems, hospitals, and private practices worldwide. Benefits of CDI's at-home breath testing program include:

• Third-party billing with insurance coverage on most tests, plus full coverage with no balance billing for Medicare patients.
• The lowest maximum out-of-pocket cost to patients available on the market.
• Fast and flexible direct-to-patient shipping, one business day turnaround time for results, and dedicated customer service and patient outreach.
• Improved staff efficiency, reduced overhead, and more revenue opportunities for healthcare practices.

CDI was recently recognized as one of the Top 100 Healthcare Technology Companies of 2022 by The Healthcare Technology Report.

To learn more, visit https://commdx.com/